Digital quantitation of bridging fibrosis and septa reveals changes in natural history and treatment not seen with conventional histology
SHG/TPEF microscopy with AI provides greater granularity and precision in assessing fibrosis dynamics in patients with bridging fibrosis, thus advancing knowledge development of fibrosis evolution in natural history and in clinical trials.
Authors
- David E. Kleiner (ORCID: https://orcid.org/0000-0003-3442-4453)
- Yayun Ren (ORCID: https://orcid.org/0000-0002-8613-5728)
- Elaine Chng (ORCID: https://orcid.org/0009-0007-8535-2281)
- Nikolai V. Naoumov (ORCID: https://orcid.org/0009-0009-3091-4990)
- Arun Jayant Sanyal (ORCID: https://orcid.org/0000-0001-8682-5748)
- Dean Tai (ORCID: https://orcid.org/0000-0002-6166-5618)
- Dominique Brees
- Chandrassegar Saravanan (ORCID: https://orcid.org/0000-0003-3214-5696)
Institutions
- Novartis (Switzerland) (CH)
- Boston Biomedical Research Institute (US)
- Virginia Commonwealth University (US)
- Novartis (United States) (US)
- National Cancer Institute (US)
- Histoindex (Singapore) (SG)
- University College London (GB)
Publication Details
- Journal
- Liver International
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1111/liv.16092
- Citations
- 6
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.32
Funders
- National Institutes of Health